Neuropharmacology | 2019
Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats
Abstract
ABSTRACT Steroids exert a profound influence on behavioral reactivity, by modulating the functions of most neurotransmitters and shaping the impact of stress and sex‐related variables on neural processes. This background ‐ as well as the observation that most neuroactive steroids (including sex hormones, glucocorticoids and neurosteroids) are synthetized and metabolized by overlapping enzymatic machineries ‐ points to steroidogenic pathways as a powerful source of targets for neuropsychiatric disorders. Inhibitors of steroidogenic enzymes have been developed and approved for a broad range of genitourinary and endocrine dysfunctions, opening to new opportunities to repurpose these drugs for the treatment of mental problems. In line with this idea, preliminary clinical and preclinical results from our group have shown that inhibitors of key steroidogenic enzymes, such as 5&agr;‐reductase and 17,20 desmolase‐lyase, may have therapeutic efficacy in specific behavioral disorders associated with dopaminergic hyperfunction. While the lack of specificity of these effects raises potential concerns about endocrine adverse events, these initial findings suggest that steroidogenesis modulators with greater brain specificity may hold significant potential for the development of alternative therapies for psychiatric problems. This article is part of the Special Issue entitled ‘Drug Repurposing: old molecules, new ways to fast track drug discovery and development for CNS disorders’. HighlightsSteroids exert profound influence on behavioral regulation.Neuroactive steroids modulate the effects of stress and sex‐related variables.Steroidogenic pathways may provide novel targets to modulate dopaminergic signaling.Steroidogenesis inhibitors may hold potential for neuropsychiatric therapy.